Clinical Trials Logo

Filter by:
NCT ID: NCT05779995 Recruiting - RSV Infection Clinical Trials

A Study To Evaluate the Safety of XW001 Inhalation in Children With RSV

Start date: April 20, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a randomized, double-blind, placebo-controlled Phase Ib/IIa study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and immunogenicity of XW001 inhalation in children with RSV infection in China

NCT ID: NCT05779917 Recruiting - Pancreas Cancer Clinical Trials

Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers

Start date: March 10, 2023
Phase: Phase 1
Study type: Interventional

The second generation of mesothelin targeted CAR-T cells that secret a fusion protein of IL21 and scfv against PD1 have been constructed and their anti-cancer function has been verified by multiple in vitro and in vivo studies. Clinical studies will be performed to test anti-cancer function of the CAR-T cells for immunotherapy of human cancer patients with Mesothelin expressions. In this phase I study, the safety, tolerance, and preliminary efficacy of the Mesothelin-CAR-T cell immunotherapy on human cancers will firstly be evaluated.

NCT ID: NCT05779644 Recruiting - Clinical trials for Diabetes Mellitus, Type 2

Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus

Start date: February 23, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to analyze the effects of GLP-1RA on blood glucose, body weight, glucose and lipid metabolism and fat distribution in overweight/obese patients with type 2 diabetes mellitus.

NCT ID: NCT05779579 Recruiting - COVID-19 Clinical Trials

Study of HS-10517 in Chinese Adult Participants

Start date: February 1, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

A Phase I/II, randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, pharmacokinetics and primary efficacy of HS-10517 in Chinese adult participants.

NCT ID: NCT05779514 Recruiting - Tumour Clinical Trials

Effect of Mirabegron on Promoting Brown Adipose Tissue Activation

Start date: August 18, 2022
Phase: N/A
Study type: Interventional

In previous preclinical studies, our group found that Mirabegron, a clinical drug, could activate brown adipose tissue and inhibit tumor growth in tumour-bearing mice.Investigators look forward to further evaluating the effect of Mirabegron-mediated brown adipose tissue activation, so as to provide new drug applications for clinical cancer prevention and treatment

NCT ID: NCT05779215 Recruiting - Clinical trials for Acute Ischemic Stroke

Registry of Acute Ischemic Stroke With Large- or Medium-vessel Occlusion

LOMEVO
Start date: April 25, 2023
Phase:
Study type: Observational [Patient Registry]

This study is designed to observe the treatment options in real-world clinical practice as well as the safety and efficacy of different treatment strategies.

NCT ID: NCT05779163 Recruiting - Clinical trials for Advanced Malignant Tumors

A Phase I/II Clinical Trial of LBL-033 in the Treatment of Advanced Malignant Tumors

Start date: April 14, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This trial is an open and multicenter phase I/II clinical study, which aims to evaluate the safety, tolerability, PK characteristics, immunogenicity, and effectiveness.

NCT ID: NCT05779150 Recruiting - Pruritus Clinical Trials

Efficacy of CeraVe® Moisturizing Cream on Skin Pruritus in Elderly Patients

Start date: February 26, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to evaluate the CeraVe® moisturizing cream's efficiency on the improvement of skin barrier in patients with chronic elderly pruritus. The main questions it aims to answer are: type of study: clinical trial participant population:in patients with chronic elderly pruritus [question 1] Evaluate the CeraVe® moisturizing cream's efficiency on the improvement of skin barrier in patients with chronic elderly pruritus, including improvements of redness, dryness/squamation, itching, burning, tingling, tightness and other factors. [question 2] Evaluate the tolerance of CeraVe® Moisturising Cream. [question 3] Evaluate the product experience of patients who were utilizing CeraVe® Moisturising Cream. This trial utilizing simple randomization, the left and right calves of paticipants were randomly divided into test side(applicating CeraVe® Moisturising Cream ) and control side (applicating Standard Cream)according to random number representation. Grouping results were double-blinded.

NCT ID: NCT05778955 Recruiting - Clinical trials for Pediatric Soft Tissue Sarcoma

Study on Dynamic CtDNA Analysis in Pediatric Soft Tissue Sarcoma

Start date: October 1, 2022
Phase:
Study type: Observational

Pediatric soft tissue sarcoma is made up of different subtypes, some of which have distinct genetic alterations. Fusion variants were found in about 43% of bone and soft tissue sarcoma samples. Ewing sarcoma is characterized by recurrent chromosome translocation, with up to 95% of cases showing EWS-ETS translocation. The genetic features of the tumor can change as it spreads or shrinks, and can also be influenced by treatment. To better understand treatment response and predict relapse early, our study collects liquid samples such as blood, bone marrow, or cerebrospinal fluid at various points during treatment. We then use next-generation sequencing to dynamically monitor the unique genetic profile of the tumor. Additionally, our research may identify new genetic targets and suggest potential treatment options.

NCT ID: NCT05778318 Recruiting - COVID-19 Pneumonia Clinical Trials

Efficacy of Lianhua Qingwen in Treating Patients Infected With the Omicron Variant of the COVID-19

Start date: March 20, 2023
Phase:
Study type: Observational

A retrospective analysis was conducted on patients infected with the Omicron variant of COVID-19 diagnosed from August 2022 to now. Patients were divided into observation groups and control groups according to whether or not oral Lianhua Qingwen granules were used. Through data analysis and follow-up, the effectiveness of Lianhua Qingwen in treating patients infected with the Omicron variant of COVID-19 was discussed.